Plain-English translation of NCT06082336 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new device called MaGIA IBC that can quickly detect three serious blood-borne infections—HIV, hepatitis B, and hepatitis C—from a single blood sample. The device is designed to work with different types of blood samples (from a vein or a finger prick) and provide results faster than traditional lab tests. Researchers want to confirm that this device works accurately and reliably before it becomes available for widespread use.
Currently, screening for these three infections often requires separate tests or results take time to get back. This trial exists to see if the MaGIA IBC device can offer a faster, simpler way to screen for all three infections at once, especially in settings where quick results are needed.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will have blood drawn by vein and/or a small finger prick to test the new device. The study has two phases: first, researchers will fine-tune how the device works, and then they will test it more broadly to confirm it gives accurate results. Your participation will help researchers understand if this device can reliably detect these three infections in different types of blood samples.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
France